Provided herein are compounds and compositions useful in increasing PPARδ activity. The compounds and compositions provided herein are useful for the treatment of PPARδ related diseases (e.g., muscular diseases, vascular disease, demyelinating disease, and metabolic diseases).

A lobamide compound according to an embodiment of the present disclosure is represented by Formula 1. The lobamide compound has excellent PTP-1B inhibitory activity that is far higher than that of conventional lobaric acid derivatives and which can be orally administered, and thus is very effective in the prevention or treatment of diabetes or obesity through oral administration.

A lobamide compound according to an embodiment of the present disclosure is represented by Formula 1. The lobamide compound has excellent PTP-1B inhibitory activity that is far higher than that of conventional lobaric acid derivatives and which can be orally administered, and thus is very effective in the prevention or treatment of diabetes or obesity through oral administration.

The present invention relates to the field of medicine. In particular, it relates to the use of tetracycline derivatives in the treatment or prevention of a neurodegenerative or neuroinflammatory disease, such as Parkinson's disease.

The present invention relates to the field of medicine. In particular, it relates to the use of tetracycline derivatives in the treatment or prevention of a neurodegenerative or neuroinflammatory disease, such as Parkinson's disease.

The present invention relates to dipeptidyl ketoamide m-methoxyphenyl derivatives and their use in the treatment of diseases and conditions associated with elevated calpain activity, such as heart injury caused by infarction, ischemia with or without reperfusion, neurodegenerative disorders, malaria, diabetic nephropathy, neurotoxicity induced by HIV virus, cancer, and fibrotic diseases.

The present invention relates to dipeptidyl ketoamide m-methoxyphenyl derivatives and their use in the treatment of diseases and conditions associated with elevated calpain activity, such as heart injury caused by infarction, ischemia with or without reperfusion, neurodegenerative disorders, malaria, diabetic nephropathy, neurotoxicity induced by HIV virus, cancer, and fibrotic diseases.

Provided herein are deuterated compounds and compositions useful in increasing PPARδ activity. The compounds have a formula ##STR00001##
where L.sup.5 comprises at least one deuterium. Exemplary species include ##STR00002##
The compounds and compositions provided herein are useful for the treatment of PPARδ related diseases (e.g., muscular diseases, vascular disease, demyelinating disease, and metabolic diseases).

Provided herein are deuterated compounds and compositions useful in increasing PPARδ activity. The compounds have a formula ##STR00001##
where L.sup.5 comprises at least one deuterium. Exemplary species include ##STR00002##
The compounds and compositions provided herein are useful for the treatment of PPARδ related diseases (e.g., muscular diseases, vascular disease, demyelinating disease, and metabolic diseases).

Disclosed are an aromatic acetylene or aromatic ethylene compound, an intermediate, a preparation method, a pharmaceutical composition and a use thereof. The aromatic acetylene or aromatic ethylene compound has a significant inhibitory effect on PD-1 and PD-L1, and can effectively relieve or treat cancers and other related diseases. ##STR00001##